<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845348</url>
  </required_header>
  <id_info>
    <org_study_id>TD0307.03</org_study_id>
    <nct_id>NCT03845348</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Shampoo TD03 and TD07 in Scalp Diseases</brief_title>
  <acronym>TD0307</acronym>
  <official_title>Đánh giá hiệu quả điều trị viêm da dầu ở đầu của dầu gội Thái Dương 3 và Thái Dương 7 (A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy Shampoos TD03 and TD07 in Scalp Diseases)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunstar Joint Stock Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Big Leap Clinical Research Support Joint Stock Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunstar Joint Stock Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scalp Conditions are common chronic skin inflamations with the occurence rate of 1 - 5 %
      among the population. TD03 shampoo and TD07 shampoo are widely used to avoid hair loss with
      successful rate reaching nearly 95%. This trial is going to evaluate the efficacy of getting
      rid of dandruff as well as the safety of the investigational products in comparison to a
      reference (ketoconazole 2%) during a 4-week treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scalp Conditions are common chronic skin inflamations with the occurence rate of 1 - 5 %
      among the population. TD03 shampoo and TD07 shampoo are widely used to avoid hair loss with
      successful rate reaching nearly 95%. With herbal ingredients including Gleditsia, Morus alba,
      Ocimum tenuiflorum, Oroxylum indicum, Ageratum conyzoides, the investigational products could
      reduce the severity of inflamation, infection and help to prevent hair loss. This trial is
      planning to evaluate the efficacy of the IPs in terms of inflamation reduction, dandruff
      reduction on subjects using the IPs compared to a reference (ketoconazole 2%).

      The trial is intended to last for 18 months with subject visits and 3 arms (122 subjects per
      arm). The first arm receive TD3 while TD7 is provided to the second arm in comparison to the
      placebo of the last arm. It will be conducted at National Hospital of Dermato - Venerology,
      Vietnam.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in IGA scale at 4 week-treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change from baseline in IGA scale at 4 week-treatment of TD3 and TD7 compared to that of Ketoconazole 2% shampoo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The numbers of subjects with AE/SAE</measure>
    <time_frame>4 weeks</time_frame>
    <description>The numbers of subjects with AE/SAE as defined in the protocol.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Scalp Dermatitis</condition>
  <arm_group>
    <arm_group_label>TD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD3, bi-daily x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD7, bi-daily x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoconazole 2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketoconazole 2% shampoo bi-daily x 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TD03</intervention_name>
    <description>Shampoo TD 3 days</description>
    <arm_group_label>TD3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TD07</intervention_name>
    <description>Shampoo TD 7 days</description>
    <arm_group_label>TD7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole 2% Shampoo</intervention_name>
    <description>Ketoconazole 2% Shampoo</description>
    <arm_group_label>Ketoconazole 2%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old and signed the ICF.

          -  Diagnosed with head skin inflamtion with IGA &lt;= 3.

          -  Voluntary sign the ICF before any procedures.

          -  No hypersentivity to the IP.

        Exclusion Criteria:

          -  Use oral antifungal 1 month prior to the trial participation or topical antifungal 2
             weeks prior to the trial participation.

          -  Suffering chronic or acute diseases that may affect the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phuong Minh Pham Thi</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital of Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Van Nguyen Thi Hong, MSC</last_name>
    <phone>(+84) 916451269</phone>
    <email>vannh@thaiduong.com.vn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nationa Hospital of Dermatology</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Pham Thi Minh</last_name>
      <phone>04.3852.1179</phone>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>February 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

